Medical Cannabis Research

Osteoarthritis Pain And Cannabinoids

Osteorthritis Pain And CannabinoidsInformation comes from scientist in the UK and USA, published in PLOS ONE in 2013. Osteoarthritis pain is challenging to treat, with chronic pain leading to central sensitization. Cannabinoids can help. This data provides new clinically relevant evidence that joint damage and spinal CB2 receptor expression are correlated combined with converging pre-clinical evidence that activation of CB2 receptors inhibits central sensitization and its contribution to the manifestation of chronic OA pain. These findings suggest that targeting CB2 receptors may have therapeutic potential for treating OA pain.


Anandamide Inhibits Breast Tumor-Induced Angiogenesis

Anandamide Inhibits Breast Tumor-Induced AngiogenesisAnandaminde and breast cancer – more evidence. This 2014 study out of Italy, published in the journal Translational Medicine, found that following anandamide treatment, MDA-MB-231 cells lose their ability to stimulate endothelial cells proliferation in vitro, due to a significant inhibition of all the pro-angiogenic factors produced by these cells. This finding adds another piece of evidence to the anti-tumor efficacy of anandamide in breast cancer.


THC Reduces Human Breast Cancer Cell Proliferation

THC Reduces Human Breast Cancer Cell Proliferation Breast cancer – Little is known about the effect of cannabinoids on the cell cycle, the main process controlling cell fate. This study out of Spain, published in a 2006 issue of Cancer Research, shows that Δ9-tetrahydrocannabinol (THC), through activation of CB2 cannabinoid receptors, reduces human breast cancer cell proliferation by blocking the progression of the cell cycle and by inducing apoptosis


Marijuana Use In Hepatitis C Infection

Marijuana Use In Hepatitis C Infection
From 2014 research published in the Canadian Journal of Gastroenterology on the use of cannabis while being treated for Hepatitis C comes this study that concludes: “Our analysis did not identify clear benefit or harm attributable to marijuana use on measures of liver histology.”


Medical Cannabis Laws and Opioid Analgesic Overdose Mortality

Medical Cannabis Laws and Opioid Analgesic Overdose Mortality
As reported in the August, 2014 issue of JAMA Internal Medicine, this research shares an examination of the association between medical cannabis laws and opioid analgesic overdose mortality. Each year after implementation of the law showed that such laws were associated with a lower rate of overdose mortality that generally strengthened over time.


Stress-Induced Anxiety: Behavioral Reversal Through Endocannabinoid Augmentation

Stress Induced Anxiety and Cannabis | Cannabis for Anxiety
Published in the July 2014 issue of Translational Psychiatry, this study out of Vanderbilt University provides support that endocannabinoid augmentation is a viable pharmacological strategy for the treatment of stress-related neuropsychiatric disorders.


Clinical Endocannabinoid Deficiency (CECD)

Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?
This 2004 study by Ethan Russo, published in the journal Neuroendocrinology, examines the concept of clinical endocannabinoid deficiency and the prospect that it could underlie the pathophysiology of migraine, fibromyalgia, irritable bowel syndrome and other functional conditions alleviated by clinical cannabis.